Kamath has over 25 years of experience across India, South Asia and ASEAN markets
MSD in India has announced leadership change. KG Ananthakrishnan (KG) current MD of MSD in India will retire in the beginning of 2017 and Vivek Vasudev Kamath will assume role of MD Designate from December 16, 2016. MSD in India operates its business in India through three legal entities, MSD Pharmaceuticals, Organon (India), and Fulford (India).
Kamath joined MSD in India in July 2012 and is currently the Business Unit Director for Cardiovascular Metabolics and Market Access. KG and Kamath will work together to ensure smooth transition of business responsibilities.
Announcing the leadership change, Jan Van Acker, President Asia Pacific Region, MSD said, “I thank KG for his leadership and his contributions to MSD over the past ten years and congratulate Kamath on assuming the role of MD of MSD in India. MSD has a robust succession planning process through which Kamath was identified to lead MSD in India and to deliver on our commitment to patients and communities in the country. He has successfully led our cardiovascular metabolics and market access businesses and has fostered collaborative relationships with our customers and business partners, while delivering strong growth”
Kamath has over 25 years of experience across India, South Asia and ASEAN markets. He brings rich experience with leading Indian and Multinational healthcare organisations in marketing, sales and general management. He has managed portfolios in prescription, over-the counter (OTC) & Diagnostics segments, partnering with healthcare professionals, consumers, diverse trade channels and government/ non-government healthcare entities.